Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 307-315

  Karp, Judith E ^a,d   Ross, Douglas D ^a,b   Yang, Weidong ^a   Tidwell, Michael L ^a   Wei, Yuetong ^a   Greer, Jacqueline ^a   Mann, Dean L ^a   Nakanishi, Takeo ^a   Wright, John J ^c   Dmitri Colevas, A ^c  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DIATRIZOATE; FICOLL; FLAVOPIRIDOL; FLUORESCEIN DIACETATE; PROPIDIUM IODIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER GROWTH; CELL CULTURE; CELL CYCLE S PHASE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; CELL DIVISION; CELL SURVIVAL; COLORING AGENTS; FEMALE; FLAVONOIDS; HL-60 CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PIPERIDINES; PROPIDIUM; S PHASE; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 12244294475     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Baudard, M., Beauchamp-Nicoud, A., Delmer, A., Rio, B., Blanc, C., Zittoun, R., and Marie, J. P. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia (Baltimore), 13: 1481-1490, 1999.
2. Buchner, T., Hiddeman, W., Wormann, B., Loffler, H., Gassmann, W., Haferlach, T., Fontsch, C., Haase, D., Schoch, C., Hossfield, D., Lengfelder, E., Aul, C., Heyll, A., Maschmeyer, G., Ludwig, W. D., Sauerland, M. C., and Heinecke, A. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 93: 4116-4124, 1999.
3. Cassileth, P. A., Harrington, D. P., Appelbaum, F. R., Lazarus, H. M., Rowe, J. M., Paietta, E., Willman, C., Hurd, D. D., Bennett, J. M., Blume, K. G., Head, D. R., and Wiernik, P. H. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med., 339: 1649-1656, 1998.
4. Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., Clark, R. E., and the Medical Research Council Adult Leukemia Working Party. Attempts to improve outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood, 98: 1302- 1311, 2001.
5. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C. J., Wheatley, K., Burnett, A. K., Goldstone, A. H., and the Medical Research Council Adult Leukemia Working Party. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98: 1312-1320, 2001.
6. Hiddemann, W., Kern, W., Schoch, C., Fonatsch, C., Heinecke, A., Wormann, B., and Buchner, T. Management of acute myeloid leukemia in elderly patients. J. Clin. Oncol., 17: 3569-3576, 1999.
7. Karp, J. E., and Smith, M. A. The molecular pathogenesis of treatment-induced (secondary) leukemias: foundations for treatment and prevention. Semin. Oncol., 24: 103-113, 1997.
8. Hoelzer, D., Ludwig, W. D., Thiel, E., Gassmann, W., Loffler, H., Fonatsch, C., Rieder, H., Heil, G., Heinze, B., Arnold, R., Hossfeld, D., Buchner, T., Koch, P., Freund, M., Hiddemann, W., Maschmeyer, G., Heyll, A., Aul, C., Faak, T., Kuse, R., Ittel, T. H., Gramatzki, M., Diedrich, H., Kolbe, K., Uberla, K., et al. Improved outcome in adult B cell acute lymphoblastic leukemia. Blood, 87: 495-508, 1996.
9. Kantarjian, H. M., O'Brien, S., Smith, T. L., Cortes, J., Giles, F. J., Beran, M., Pierce, S., Huh, Y., Andreeff. M., Koller, C., Ha, C. A., Keating, M. J., Murphy, S., and Freireich, E. J. Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J. Clin. Oncol., 18: 547-561, 2000.
10. Petersdorf, S. H., Kopecky, K. J., Head, D. R., Boldt, D. H., Balcerzak, S. P., Wun, T., Roy, V., Veith, R. W., and Appelbaum, F. R. Comparison of the LIOM consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia (Baltimore), 15: 208-216, 2001.
11. Thomas, X., Danaila, C., Le, Q. H., Sebban, C., Troncy, J., Charrin, C., Lheritier, V., Michallet, M., Magaud, J. P., and Fiere, D. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia (Baltimore), 15: 1811-1822, 2001.
12. Faderl, S., Kantarjian, H. M., Talpaz, M., and Estrov, Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood, 91: 3995-4019, 1998.
13. Wetzler, M., Dodge, R. K., Mrozek, K., Carroll, A. J., Tantravahi, R., Block, A. W., Pattenati, M. J., Le Beau, M. M., Frankel, S. R., Stewart, C. C., Szatrowski, T. P., Schiffer, C. A., Larson, R. A., and Bloomfield, C. D. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Acute Leukemia Group B experience. Blood, 93: 3983-3993, 1999.
14. Burke, P. J., Karp, J. E., Braine, H. G., and Vaughan, W. P. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res., 37: 2138-2146, 1977.
15. Karp, J. E., and Burke, P. J. Growth response of residual leukemia after initial drug therapy. Cancer Res., 46: 4205-4207, 1986.
16. Karp, J. E., Donehower, R. C., Enterline, J. P., Dole, G. B., Fox, M. G., and Burke, P. J. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood. 73: 24-30, 1989.
17. Karp, J. E., Donehower, R. C., Dole, G. B., and Burke, P. J. Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-β-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia. Blood, 69: 1134-1140, 1987.
18. Archimbaud, E., Thomas, X., Leblond, V., Michallet, M., Fenaux, P., Cardonnier, C., Dreyfus, F., Troussard, X., Jaubert, J., Travade, P., Troncy, J., Assouline, D., and Fiere, D. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J. Clin. Oncol., 13: 11-18, 1995.
19. Geller, R. B., Burke, P. J., Karp, J. E., Humphrey, R. L., Braine, H. G., Tucker, R. W., Fox, M. G., Zahurak, M., Morrell, L., Hall, K. L., and Piantadosi, S. A. two-step timed sequential treatment for acute myelocytic leukemia. Blood, 74: 1499-1506, 1989.
20. Martino, R., Guardia, R., Altes, A., Sureda, A., Brunei, S., and Sierra, J. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the Phase II GEMIA protocol. Haematologica, 84: 226-230, 1999.
21. Woods, W. G., Alonzo, T. A., Lange, B. J., Jeha, S., and Estey, E. H. Acute myeloid leukemia (AML) in adolescents and young adults (AYAs): comparison of outcomes between patients treated on childhood or adult protocols. Blood, 98 (Suppl. 1): 462a, 2001.
22. Woods, W. G., Kobrinsky, N., Buckley, J. D., Lee, J. W., Sanders, J., Neudorf, S., Gold, S., Barnard, D. R., DeSwarte, J., Dusenbery, K., Kalousek, D., Arthur, D. C., and Lange, B. J. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 87: 4979-4989, 1996.
23. Ohno, Y., Spriggs, D., Matsukage, A., Ohno, T., and Kufe, D. Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase β. Cancer Res., 48: 1494-1498, 1988.
24. Datta, R., Banach, D., Kojima, H., Talanian, R. V., Alnemri, E. S., Wong, W. W., and Kufe, D. W. Activation of the CPP32 protease in apoptosis induced by 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood. 88: 1936-1943, 1996.
25. Maik, R. G., Kattice, S. L., Bhat, S. V., Alreja, B., de Souza, N. J., and Rupp, R. H. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectareferum: isolation, structure and total synthesis. Tetrahedron, 44: 2081-2086, 1988.
26. Senderowicz, A. M., and Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (Bethesda), 92: 376-387, 2000.
27. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4856-4861, 1996.
28. Konig, A., Schwartz, G. K., Mohammad, R. M., Al-Katib, A., and Gabrilove, J. L. The novel cyclin-dependent kinase inhibitor flavopiridol down-regulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood, 90: 4307-4312, 1997.
29. Parker, B. W., Kaur, G., Nieves-Neira, W., Taimi, M., Kohlhagen, G., Shimizu, T., Losiewicz, M. D., Pommier, Y., Sausville, E. A., and Senderowicz, A. M. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood, 91: 458-465, 1998.
30. Decker, R. H., Dai, Y., and Grant, S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ., 8: 715-724, 2001.
31. De Azevedo, W. F., Jr., Mueller-Diekmann, H-J., Schulze-Gahmen, U., Worland, P. J., Sausville, E., and Kim, S-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc. Natl. Acad. Sci. USA, 93: 2735-2740, 1996.
32. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK 4 in human breast carcinoma cells. Cancer Res., 56: 2973-2978, 1996.
33. Losiewicz, M. D., Carlson, B. A., Kaur, G., Sausville, E. A., and Worland, P. J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem. Biophys. Res. Commun., 201: 589-595, 1994.
34. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem. Pharmacol., 46: 1831-1840, 1993.
35. Carlson, B., Lahusen, T., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., and Senderowicz, A. M. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4643, 1999.
36. Mellilo, G., Sausville, E. A., Cloud, K., Lahusen, T., Varresio, L., and Senderowicz, A. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res., 59: 5433-5437, 1999.
37. Aguayo, A., Estey, E. H., Kantarjian, H., Mansouri, T., Gidel, C., Keating, M., Giles, F., Estrov, Z., Barlogie, B., and Albitar, M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood, 94: 3717-3721, 1999.
38. Aguayo, A., Kantarjian, H., Manshouri, T., Gidel, C., Estey, E., Thomas, D., Koller, C., Estrov, Z., O'Brien, S., Keating, M., Freireich, E., and Albitar, M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood, 96: 2240-2245, 2000.
39. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med., 8 (Suppl.): S32-S37, 2002.
40. Chao, S. H., and Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276: 31793-31799, 2001.
41. Price, D. H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol. Cell. Biol., 20: 2629-2634, 2000.
42. Lain, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A., Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol., 2: 1-11, 2001.
43. Bible, K. C., Bible, R. H., Jr., Kottke, T. J., Svingen, P. A., Xu, K., Pang, Y-P., Hajdu, E., and Kaufmann, S. H. Flavopiridol binds to duplex DNA. Cancer Res., 60: 2419-2428, 2000.
44. Kaufmann, S. H., Karp, J. E., Svingen, P. A., Krajewski, S., Burke, P. J., Gore, S. D., and Reed, J. C. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood, 91: 991-1000, 1998.
45. Kitada, S., Zapata, J. M., Andreeff, M., and Reed, J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96: 393-397, 2000.
46. Zhang, B., Gojo, I., and Fenton, R. G. MCL-1 is a critical survival factor for multiple myeloma. Blood, 99: 1885-1893, 2002.
47. Lee, Y. K., Tidwell, M. L., Kaufmann, S. H., Karp, J. E., and Bible, K. C. Flavopiridol disrupts STAT-3/DNA binding and down-regulates the downstream antiapoptotic protein MCL-1 in vivo in leukemic cells from flavopiridol-treated AML patients. Proc. Am. Assoc. Cancer Res., 43: 127, 2002.
48. Karp, J. E., Yang, W., Tidwell, M. L., Greer, J., Wei, D., Guo, C., and Ross, D. D. Timed sequential therapy (TST) of acute leukemia with flavopiridol: in vitro model for a Phase I clinical trial. Blood, 98 (Suppl. 1): 594a, 2001.
49. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997.
50. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998.
51. Donehower, R. C., Karp, J. E., and Burke, P. J. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat. Rep., 70: 1059-1065, 1986.
52. Krishan, A. Rapid flow cytometric analysis of mammalian cell cycle by propidium iodide staining. J. Biol. Chem., 166: 188-193, 1975.
53. Ross, D. D., Joneckis, C. C., Ordonez, J. V., Sisk, A. M., Wu, R. K., Hamburger, A. W., and Nora, R. E. Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number. Cancer Res., 49: 3776-3782, 1989.
54. Harvey, S., Decker, R., Dai, Y., Schaefer, G., Tang, L., Kramer, L., Dent, P., and Grant, S. Interactions between 2-flouroadenine 9-β-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells. Clin. Cancer Res., 7: 320-330, 2001.
55. Tang, L., Boise, L. H., Dent, P., and Grant, S. Potentiation of 1-β-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01). Biochem. Pharmacol., 60: 1445-1456, 2000.
56. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E., and Grever, M. R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood, 92: 3804-3816, 1998.
57. Rapoport, A. P., Simons-Evelyn, M., Chen, T., Sidell, R., Luhowskyj, S., Rosell, K., Obrig, T., Hicks, D., Hinkle, P., Nahm, M., Insel, R. A., and Abboud, C. N. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. Blood Cells Mol. Dis., 27: 610-624, 2001.